About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
Featured
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to June 2020
Billion doses of treatment supplied from January 2012 to June 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to June 2020
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 30 November 2020 (see announcement). Disclaimer | Product availability data from MPP sublicensees: last updated on 20 January 2021 (data as of 30 September 2020) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Key Publications
Annual Reports
06 October 2020
Twitter Feed

MedicinesPatentPool @MedsPatentPool
Today is #ZeroDiscrimination Day. ✅Everyone should have rapid access to effective and affordable treatments, no matter who they are and where they live ❌No one should have to face stigma and discrimination in their journey #LeavingNoOneBehind #EndInequalities #HealthForAll https://t.co/VaorC9icW5

MedicinesPatentPool @MedsPatentPool
📣#JustAnnounced: MPP and @WIPO strengthen collaboration to further advance strategies and information sharing for #PublicHealth, esp. on: ✅intellectual property management strategies ✅information sharing ✅capacity building ➡️ https://t.co/D1gc4xJ9Go https://t.co/8QAqVqCnWp

MedicinesPatentPool @MedsPatentPool
MPP’s @eburrone at today’s webinar by @iavi @wellcometrust @DBTIndia: “Early engagement and innovative #partnerships are prerequisites to the successful manufacture of monoclonal antibodies in #LMICs” #Therapeutics // Virtual #ActforAccess https://t.co/rW40oaqeAR https://t.co/NNI6uhyKTE

MedicinesPatentPool @MedsPatentPool
🗓️Tomorrrow: Join our ED @CharlieGore & others in @KEI_DC’s roundtable on pathways to scale up manufacturing capacity for #COVID19 #vaccines ⏰When: Friday, 19 Feb 2021, 15h to 17h CET To register: 📨Email vaccine-roundtable@keionline.org More info 👉https://t.co/yMYPVgiyyH https://t.co/umqf9oTBLe